A Titer That Might Block the Cure: Deciding Whether to Spend His One Shot at Gene Therapy Now
He has exactly one chance at hemophilia B gene therapy — re-dosing isn't possible if it doesn't take — and a low but detectable anti-AAV5 antibody titer means nobody can promise this is the try that works.
D.K., a 34-year-old graphic designer with moderate-severe hemophilia B, has been on prophylactic extended-half-life factor IX twice weekly since his twenties, well-controlled with roughly two breakthrough joint bleeds a year, and has spent the past several months reading everything he can find about etranacogene dezaparvovec, the AAV5-based gene therapy approved for hemophilia B, hoping it might let him stop the infusions that have shaped his adult life around a twice-weekly schedule. His pre-treatment workup found a low but clearly detectable anti-AAV5 neutralizing antibody titer of 1:340, most likely from an unremembered natural AAV exposure at some point in his life rather than anything medically documented, and this is the fact the entire visit now turns on.
The HOPE-B trial that established etranacogene dezaparvovec's efficacy allowed patients with detectable but low-titer anti-AAV5 antibodies, and every participant who received a full dose at a titer up to 1:678 achieved a therapeutic response, with no correlation at all between titer and factor IX activity inside that band — his 1:340 sits comfortably within it. What the trial could not establish is where the band ends: the single non-responder had a titer of 1:3212, nothing was studied between those two figures, and the permissive cutoff is formally unknown. The antibody-positive group as a whole also expressed somewhat lower mean factor IX than the antibody-negative group, so his status is not simply neutral. Unlike factor IX prophylaxis, which he could always resume unchanged if it stops meeting his needs, gene therapy is functionally a one-time treatment — a second AAV5 dose is not a real option once his immune system has been exposed to the vector, whether or not the first dose achieves the expression his antibody status makes uncertain. He has told the team plainly that a partial answer bothers him: he doesn't want a probability, he wants to know if it will actually work, and no test available today can tell him that with certainty before he spends the one attempt he gets.
He has been candid throughout his years of factor IX prophylaxis about how much the twice-weekly schedule has shaped decisions he didn't expect a bleeding disorder to touch — turning down a promotion that would have required more travel, building his social plans around infusion days — which is part of why the appeal of a genuinely one-time treatment is not abstract to him, even as he says clearly that he doesn't want hope to substitute for an honest answer about the odds.
In clinic, after the antibody result came back
HOPE-B specifically included patients with detectable anti-AAV5 antibodies, and every one of them dosed at a titer up to 1:678 responded — his 1:340 is squarely inside that band, not at its edge. There's no cutoff that puts him outside eligibility, and his titer won't improve by waiting — if anything, a future incidental exposure could push it higher and close this window rather than keep it open.
I'd want to be direct about what 'most' means here — his current regimen is well-controlled, and if it ever stops working as well, real options remain. Gene therapy doesn't have that fallback. His titer band predicts a response; it doesn't promise the magnitude of one, and the antibody-positive group ran lower on mean expression than the antibody-negative group. If he lands at the weak end of that, there's no second dose, no salvage plan — just a worse outcome he can't undo.
Trial support for eligibility isn't the same as a guarantee of individual response, and this decision, unlike almost everything else we do for him, genuinely can't be revisited once it's made.
I don't think either of you is wrong, and I don't think more clinical data alone resolves this — a repeat titer closer to his actual treatment date could tell us if it's rising, which would be genuinely useful information, but it won't eliminate the underlying uncertainty about how his specific response will land within the range HOPE-B describes.
What I'd add is that his own stated risk tolerance belongs explicitly in this decision, not as a tiebreaker after the clinical facts are settled, but as a real input alongside them — he told us directly he wants certainty nobody can give him. Naming that honestly, and letting him decide with the actual, irreducible uncertainty in view rather than a false confidence in either direction, is the honest way to close this visit today.
Not agreed, and deliberately left unresolved by the team's own design: factor IX prophylaxis continues unchanged today, a repeat anti-AAV5 titer is scheduled in six weeks, and D.K. was told directly that no test available will remove the underlying uncertainty about his individual response — the final decision was left explicitly to him, with both hematologists' full reasoning given rather than a single recommendation.